Purine Clinical Trials

Size	Price	Qty
25mg	USD 97

Clinical Trials

Several clinical trials sponsored by academic medical centers, psychiatric research institutes, and government facilities are evaluating purine-related biological responses and clinical protocols across diverse medical conditions. The research scope encompasses acute myocardial infarction, depressive and bipolar disorders, traumatic brain injury with posttraumatic stress disorder, and various malignant neoplasms, with specific investigations into post-infarction autonomic responses and psychiatric biomarkers. Ranging from combined Phase 1/Phase 2 to unspecified phases, these studies currently hold recruiting, withdrawn, or unknown recruitment statuses.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06298513	Recruiting	Acute Myocardial Infarction: Rehabilitation Phase	Istituto Auxologico Italiano	2023-05-02	--
NCT05463562	Recruiting	Depressive Disorder\|Bipolar Disorder	Max-Planck-Institute of Psychiatry	2022-02-24	--
NCT04262895	Withdrawn	Mild to Moderate TBI\|Posttraumatic Stress Disorder	VA Office of Research and Development	2021-10-01	Phase 1\|Phase 2
NCT04198051	Unknown status	Gastric Cancer\|Colon Cancer	The First Affiliated Hospital of Dalian Medical University	2019-12-20	Not Applicable
NCT04202848	Unknown status	Lung Cancer\|Breast Cancer\|Gastrointestinal Cancer\|Malignant Neoplasms	The First Affiliated Hospital of Dalian Medical University	2019-12-20	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Purine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an essential heterocyclic aromatic scaffold, purine integrates into nucleic acids and critical cofactors such as ATP and cyclic AMP to regulate fundamental enzymatic cascades and cellular bioenergetics. Interruption or regulation of purine metabolic pathways suppresses nucleotide biosynthesis and cell viability, which directly informs clinical investigations targeting neoplastic growth in gastric, breast, and lung cancers as well as neuro-psychiatric and cardiovascular conditions.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).